Company intelligence / Profile preview

first-lien

Ownership: Private
Development stage: Other

Overview

First-Lien is a biotechnology company focused on developing novel small molecule therapeutics for the treatment of cancer. The company utilizes a proprietary platform to identify and target specific vulnerabilities in tumor cells, aiming to overcome resistance to existing therapies. Their approach emphasizes the discovery of first-in-class drugs that can provide significant clinical benefits for patients with hard-to-treat malignancies. First-Lien is currently in the pre-clinical stage, advancing its lead programs toward IND-enabling studies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on first-lien.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on first-lien.

Explore the full profile